Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Bioentrepreneur
  • Published:

A successful founder off the beaten path

Nature Biotechnology volume 35, pages 900–903 (2017)Cite this article

Subjects

How to develop a new vaccine or therapeutic modality in a skeptical environment, with little biotech experience, limited resources and limited capital.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. CureVac, Tübingen, Germany

    Ingmar Hoerr

Authors
  1. Ingmar Hoerr
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Ingmar Hoerr.

Ethics declarations

Competing interests

I.H. is CEO of CureVac AG (Germany) and President of CureVac Inc. (USA).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoerr, I. A successful founder off the beaten path. Nat Biotechnol 35, 900–903 (2017). https://doi.org/10.1038/nbt.3975

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt.3975

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research